Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trialJeffrey A. Jones, John C. Byrd, Anthony R. Mato et al.|The Lancet Oncology|2017Cited by 378
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b studyJohn F. Seymour, Andrew W. Roberts, Shuo Ma et al.|The Lancet Oncology|2017Cited by 327
Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapySteven Coutré, Matthew S. Davids, Michael Y. Choi et al.|Blood|2018Cited by 132
Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective StrategyAnthony R. Mato, Colleen Dorsey, Kentson Lam et al.|Clinical Cancer Research|2020Cited by 115
Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinibMax J. Gordon, Alexey V. Danilov, Michael C. Churnetski et al.|Cancer|2018Cited by 86